

Press Release
November 13, 2012

HEALTH| INNOVATION | FLUORESCENCE IMAGING | CLINICAL TRIALS

Fluoptics Launches First Clinical Trials

GRENOBLE, France – Today Fluoptics announced the launch of the first clinical trials using their FluoBeam™ optical system for fluorescence imaging. These first trials will focus on both reconstructive and thyroid surgery.

“This new phase allows Fluoptics to take a major step on the path of our development plan,” remarked Fluoptics CEO Odile Allard. “We have already demonstrated the pertinence of fluorescence imaging in pre-clinical tests and this will allow us to demonstrate its use by surgeons in the operating room.”

A first clinical trial, concerning some 20 patients, is underway at the University Hospital Centre in Grenoble (*CHU Grenoble*) in the area of reconstructive surgery of the jaw. It aims at demonstrating the ability of fluorescence imaging to locate vessels vascularising skin grafts and to evaluate the perfusion of the graft during and after the operation. The system will use Serb Laboratories' Infracyanine® tracer.

A second clinical trial has also begun in the General Surgery department of the Sheffield Teaching Hospitals NHS Foundation Trust (UK) and will include ten patients with primary hyperparathyroidism. It aims at demonstrating that near-infrared fluorescence imaging with Methylene Blue has potential to be used in thyroid and parathyroid surgery and may help by enabling surgeons to clearly identify parathyroid glands and differentiate them from surrounding soft tissue structures.

“We are particularly excited to start this key step, as a prelude to early sales of our first fluorescence imaging device for the international market,” remarked Odile Allard.

Fluoptics intends to rapidly launch additional clinical trials on other surgical indications.

About Fluoptics

Created in 2009, Fluoptics is specialized in the development and commercialisation of innovative solutions in fluorescence imaging as a surgical aid. This technology promises a wide range of applications in oncological surgery for the resection of cancerous tumours and the detection of sentinel nodes, but also for cardiovascular, reconstructive and hepatic surgeries. Based at Minatec, in Grenoble, France, Fluoptics employs a staff of 11 with 2011 revenue of 560K €. To find out more visit: www.fluoptics.com

Media Contacts:

FLUOPTICS

Odile Allard, CEO
Tel: +33 (0)4 38 78 28 78
odile.allard@fluoptics.com
www.fluoptics.com

BRIDGE COMMUNICATION

Francis Temman
Tel: +33 (0)1 70 08 61 22 / 06 50 92 21 56
francis.temman@bridge-communication.com
www.bridge-communication.com